Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1005-1017 , July 2010

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial

  • Paul G. Richardson

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Paul G. Richardson, MD, Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA 02115.
    • ,
  • Robert J. Soiffer

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • ,
  • Joseph H. Antin

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • ,
  • Hajime Uno

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Zhezhen Jin

      Affiliations

    • Department of Biostatistics, Columbia University, New York, New York
    • ,
  • Joanne Kurtzberg

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Paul L. Martin

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Gideon Steinbach

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Karen F. Murray

      Affiliations

    • Seattle Children's Hospital, Seattle, Washington
    • ,
  • Georgia B. Vogelsang

      Affiliations

    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Allen R. Chen

      Affiliations

    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Amrita Krishnan

      Affiliations

    • City of Hope Cancer Center, Duarte, California
    • ,
  • Nancy A. Kernan

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • David E. Avigan

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • ,
  • Thomas R. Spitzer

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • ,
  • Howard M. Shulman

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Donald N. Di Salvo

      Affiliations

    • Department of Radiology, Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Carolyn Revta

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • ,
  • Diane Warren

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • ,
  • Parisa Momtaz

      Affiliations

    • Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital; Children's Hospital, and Harvard Medical School, Boston, Massachusetts
    • ,
  • Gary Bradwin

      Affiliations

    • Department of Laboratory Medicine, Children's Hospital, Boston, Massachusetts
    • ,
  • L.J. Wei

      Affiliations

    • Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts
    • ,
  • Massimo Iacobelli

      Affiliations

    • Gentium SpA, Villa Guardia, Como, Italy
    • ,
  • George B. McDonald

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Eva C. Guinan

      Affiliations

    • Department of Pediatrics, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts

Received 28 October 2009 ,Accepted 9 February 2010.

References 

  1. Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001;106:57–68
  2. McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–122
  3. Blostein MD, Paltiel OB, Thibault A, et al. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant. 1992;10:439–443
  4. Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999;5:306–315
  5. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599–3604
  6. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–267
  7. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007;13:853–862
  8. Reiss U, Cowan M, McMillan A, et al. Hepatic veno-occlusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol. 2002;24:746–750
  9. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–42
  10. Shulman HM, Fisher LB, Schoch HG, et al. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994;19:1171–1181
  11. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127:549–558
  12. McCune JS, Batchelder A, Guthrie KA, et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther. 2009;85:615–622
  13. Tay J, Tinmouth A, Fergusson D, et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:206–217
  14. Bearman SI, Lee JL, Baron AE, et al. Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89:1501–1506
  15. Bearman SI, Shen DD, Hinds MS, et al. A phase I/II study of prostaglandin E1 for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Br J Haematol. 1993;84:724–730
  16. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of preemptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica. 2006;91:795–800
  17. Eissner G, Multhoff G, Gerbitz A, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood. 2002;100:334–340
  18. Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun. 1994;200:933–937
  19. Coccheri S, Biagi G, Legnani C, et al. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol. 1988;35:151–156
  20. Berti F, Rossoni G, Biasi G, et al. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1–induced contraction in human saphenous veins. Prostaglandins. 1990;40:337–350
  21. Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost. 1994;71:507–510
  22. Falanga A, Marchetti M, Vignoli A, et al. Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. [abstract] Blood. 1999;94:146a
  23. Falanga A, Marchetti M, Vignoli A, et al. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels. [abstract] Blood. 2000;96:53a
  24. Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008;112:4343–4352
  25. Mitsiades CS, Rouleau C, Echart C, et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009;15:1210–1221
  26. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–744
  27. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122–1129
  28. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–4343
  29. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189–195
  30. Bulley SR, Strahm B, Doyle J, et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2007;48:700–704
  31. Bearman SI, Anderson GL, Mori M, et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729–1736
  32. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–864
  33. Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:935–944
  34. Eber SW, Gungor T, Veldman A, et al. Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease. Pediatr Transplant. 2007;11:49–57
  35. Schlegel PG, Haber HP, Beck J, et al. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin. Ann Hematol. 1998;76:37–41
  36. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310–2314
  37. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425–4431
  38. Platzbecker U, von Bonin M, Goekkurt E, et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant. 2009;15:101–108
  39. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:551–557
  40. Tanikawa S, Mori S, Ohhashi K, et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single-center study. Bone Marrow Transplant. 2000;26:881–886
  41. Pihusch M, Wegner H, Goehring P, et al. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients. Transplantation. 2005;80:1376–1382
  42. Carreras E, Olavarria E, Neven B, et al. Defibrotide for the treatment of veno-occlusive disease post SCT: preliminary results of EU compassionate use program in 332 patients confirms promising activity and manageable toxicity. [abstract] Blood. 2007;110:189a
  43. Al Beihany A, Al Omar H, Sahovic E, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant. 2008;41:287–291
  44. Ringden O, Remberger M, Lehmann S, et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2000;25:993–996
  45. Corbacioglu S, Honig M, Lahr G, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant. 2006;38:547–553
  46. Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant. 2007;40:79–82
  47. Bonini A, Avanzini P, Masini L, et al. Defibrotide low-dose continuous infusion from day +1 until day +21 after allogeneic stem cell transplantation as prophylaxis of veno-occlusive disease (VOD) of the liver: a single-center experience. [abstract] Blood. 2007;110(11):307b
  48. Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer. 2008;50:831–832
  49. Corbacioglu S. Update on the phase II/III study of the incidence and outcome of VOD with the prophylactic use of defibrotide in pediatric stem cell transplantation (VOD-DF Study). [abstract] Bone Marrow Transplant. 2008;41(Suppl 1s):S34
  50. Corbacioglu S. The prospective study on the incidence and outcome of VOD with the prophylactic use of defibrotide in paediatric stem cell transplantation has completed enrolment: update on the VOD-DF study. [abstract] Bone Marrow Transplant. 2009;43(Suppl 1s):S34–S35
  51. Richardson P, Kernan N, Tomblyn M, et al. A phase 3 randomized, historically controlled clinical trial investigating the use of defibrotide in the treatment of severe veno-occlusive disease post-SCT: a novel approach to the validation of a promising new drug for the treatment of a life-threatening disease. [abstract] Blood. 2007;110:189a
  52. Richardson P, Tomblyn M, Kernan N, et al. Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control. [abstract] Blood. 2009;114:272a–273a

 Financial disclosure: See Acknowledgments, page 1016.

PII: S1083-8791(10)00065-0

doi: 10.1016/j.bbmt.2010.02.009

Biology of Blood and Marrow Transplantation
Volume 16, Issue 7 , Pages 1005-1017 , July 2010

Article Tools

* Image Usage & Resolution